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In a recent issue of the Proceedings of the National Acad-
emy of Sciences, we found that Burkitt’s lymphoma caused
by Epstein–Barr Virus (EBV) used differing signaling path-
ways than sporadic Burkitts lymphoma (Cerimele et al,
2004). EBV infection was associated with high levels of re-
active oxygen and mitogen-activated protein (MAP) kinase
signaling, whereas EBV-negative Burkitts lymphoma had
very low levels of either reactive oxygen and MAP kinase
signaling. Significantly, EBV infection was associated with
hypermethylation of the p16ink4a tumor suppressor gene,
whereas EBV negative lymphomas were associated with
mutation of the p53 tumor suppressor gene. Finally, we
show that when EBV-positive lymphoma cells are treated
with a potent inhibitor of reactive oxygen, ebselen, nuclear
factor kB (NFkB) is inhibited, but MAP kinase is activated.
What do these findings have to do with cutaneous carcin-
ogenesis and inflammation?
The three most common cancers of the skin are basal
cell carcinoma (BCC), squamous cell carcinoma (SCC), and
melanoma. In BCC and SCC, mutations of p53 are ex-
tremely common, whereas in melanoma, loss of p16ink4a is
very common (Ziegler et al, 1993; Hussussian et al, 1994).
The most important carcinogen in terms of the skin is ul-
traviolet light, with UVB capable of causing direct DNA
damage as well as reactive oxygen generation, whereas
UVA is less damaging to DNA, but causes generation of
reactive oxygen (Tsao and Sober, 1998). We have previously
shown that reactive oxygen-generating carcinogens cause
hypermethylation of p16ink4a, and our current paper shows
that EBV infection, as well as specific EBV genes, such as
latent membrane protein-1 (LMP-1) generate reactive oxy-
gen (Govindarajan et al, 2002). It thus stands to reason that
UV-induced reactive oxygen may play a major role in the
development of melanoma.
Why is melanoma so much more aggressive than the
average BCC or SCC? The answer may lie in the choice of
signaling pathways. We have previously hypothesized that
p16-deficient tumors can use a variety of signaling path-
ways, including MAP kinase, PI3 kinase/akt, and reactive
oxygen signaling (Arbiser, 2004). P53-deficient tumors are
more limited in their ability to use differing signaling path-
ways, i.e., p53-deficient tumors are often highly sensitive to
reactive oxygen-generating agents such as X-irradiation,
whereas p16-deficient tumors are more resistant (Arbiser,
2004). Our data also demonstrate another important feature
of tumors. They are capable of switching signaling mech-
anisms in the face of strong inhibition of a signaling pathway
(Fig 1). The tumor cell uses a balance of signaling mech-
anisms, and inhibition of one pathway leads to rapid adap-
tation to another pathway. Some of the strongest evidence
of this comes from clinical practice. Velcade is a potent
inhibitor of NFkB signaling that is currently first-line therapy
for multiple myeloma, a tumor known to have inactivation
of p16ink4a as a common event (Barlogie et al, 2004;
Jagannath et al, 2004). Although velcade has impressive ac-
tivity in myeloma, resistance occurs commonly, and may be
because of compensatory upregulation of MAP kinase signa-
ling. Velcade has been given to patients with metastatic me-
lanoma, with less than impressive results. Although velcade
may reduce NFkB activation in metastatic melanoma, MAP
kinase activation likely compensates, given the known role
of MAP kinase in melanoma development (Cohen, 2002;
Govindarajan, 2003). Similarly, BAY 43-9006, a tyrosine kin-
ase inhibitor directed against B-raf, is not curative of me-
lanoma even though many melanomas have mutant B-raf.
Likely, effective antagonism of B-raf occurs in vivo, but the
tumor responds with NFkB activation.
Similarly, EBV infection is associated with the develop-
ment of systemic lupus erythematosus (SLE). In a recent
study, patients with SLE were found to have antibodies that
cross-react between Epstein–Barr Nuclear Antigen and Ro
autoantigen (McClain et al, 2005). What do EBV and SLE
have in common? Both are known to be associated with
overproduction of interleukin-10. In our study of Burkitts
lymphoma, we show that neutralizing antibodies against
interleukin-10 block production of reactive oxygen. It is
likely that EBV infection of a genetically susceptible indi-
vidual results in aberrant production of interleukin-10, re-
sulting in B cell proliferation and autoantibody production.
Inhibitors of reactive oxygen, such as ebselen described in
our study, may be beneficial in antagonizing interleukin-10-
induced pathology in both EBV infection and SLE (Liu et al,
2005).
Are these discoveries all bad news? The failure of single
agent-targeted therapies are disappointing, yet predictable.
Yet, this does not spell doom for these novel agents. Now
that we know that p16ink4-deficient tumors, which com-
prise the most aggressive of human tumors, can switch
signaling pathways, we can anticipate patterns of resist-
ance. These findings make the argument for concurrent or
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
xi
sequential combination therapies, i.e. Raf/MAP kinase inhi-
bition with NFkB inhibition. We have discovered multiple
ways of inhibiting NFkB activation, including compounds
familiar to the dermatologist. These include velcade, epic-
atechin gallate, honokiol, curcumin, and other drugs
(Arbiser et al, 1998; Ahmad et al, 2000; Aggarwal et al,
2004). In addition, we have developed multiple ways of in-
hibiting tyrosine kinases, and these drugs include many in
clinical use, such as glivec, iressa, herceptin, and BAY 43-
9006. Now is the time to study the optimal combinations of
these drugs in the treatment of highly malignant disorders,
such as melanoma.
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Figure 1
Alternating signaling pathways used by tumor
cells. P16-deficient neoplasms are capable of
signaling through the P42/44 ERK MAP kinase,
akt, and reactive oxygen/nuclear factor kB
(NFkB) pathways. Blockade of reactive oxygen/
NFkB leads to activation of p42/44 ERK MAP
kinase. Blockade of p42/44 ERK may lead to
compensatory upregulation of reactive oxygen/
NFkB and akt. VEGF transcription can be con-
trolled by a number of AP-1 subunits, some of
which preferentially operate under conditions of
high reactive oxygen (JunD, fra-1, fra-2) or low
reactive oxygen (c-jun,c-fos). Induction of VEGF
under conditions of low reactive oxygen often
occurs through the hypoxia inducible factor
(HIF1) pathway, whereas high reactive oxygen
favors HIF-independent pathways.
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